DZ2729A1 - Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant. - Google Patents
Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant.Info
- Publication number
- DZ2729A1 DZ2729A1 DZ990032A DZ990032A DZ2729A1 DZ 2729 A1 DZ2729 A1 DZ 2729A1 DZ 990032 A DZ990032 A DZ 990032A DZ 990032 A DZ990032 A DZ 990032A DZ 2729 A1 DZ2729 A1 DZ 2729A1
- Authority
- DZ
- Algeria
- Prior art keywords
- nhe
- preparation
- pharmaceutical compositions
- compositions containing
- new inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7636298P | 1998-02-27 | 1998-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
DZ2729A1 true DZ2729A1 (fr) | 2005-03-01 |
Family
ID=22131525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DZ990032A DZ2729A1 (fr) | 1998-02-27 | 1999-02-24 | Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant. |
Country Status (39)
Country | Link |
---|---|
US (2) | US6492401B1 (zh) |
EP (2) | EP1454902A1 (zh) |
JP (2) | JP2002504546A (zh) |
KR (4) | KR20030083004A (zh) |
CN (1) | CN1289326A (zh) |
AP (1) | AP9901478A0 (zh) |
AR (1) | AR015526A1 (zh) |
AT (1) | ATE286034T1 (zh) |
AU (1) | AU739403B2 (zh) |
BG (1) | BG104803A (zh) |
BR (1) | BR9908332A (zh) |
CA (1) | CA2321642A1 (zh) |
CO (1) | CO4980897A1 (zh) |
DE (1) | DE69922930T2 (zh) |
DK (1) | DK1056729T3 (zh) |
DZ (1) | DZ2729A1 (zh) |
EA (1) | EA003603B1 (zh) |
ES (1) | ES2237080T3 (zh) |
GT (1) | GT199900022A (zh) |
HR (2) | HRP20000550A2 (zh) |
HU (1) | HUP0204418A3 (zh) |
ID (1) | ID25505A (zh) |
IL (1) | IL136588A0 (zh) |
IS (1) | IS5548A (zh) |
NO (1) | NO20004192D0 (zh) |
NZ (1) | NZ504769A (zh) |
OA (1) | OA11450A (zh) |
PA (1) | PA8468401A1 (zh) |
PE (1) | PE20000334A1 (zh) |
PL (1) | PL342444A1 (zh) |
PT (1) | PT1056729E (zh) |
SI (1) | SI1056729T1 (zh) |
SK (1) | SK12342000A3 (zh) |
TN (1) | TNSN99028A1 (zh) |
TR (1) | TR200002480T2 (zh) |
TW (1) | TWI226329B (zh) |
WO (1) | WO1999043663A1 (zh) |
YU (1) | YU46200A (zh) |
ZA (1) | ZA991578B (zh) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200002480T2 (tr) * | 1998-02-27 | 2000-12-21 | Pfizer Products Inc. | İzaşemi tedavisi için guanidin türevleri |
FR2795726A1 (fr) * | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
UA72002C2 (en) * | 1999-10-29 | 2005-01-17 | Pfizer Prod Inc | Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage |
US6441176B1 (en) * | 1999-10-29 | 2002-08-27 | Pfizer Inc. | Method for preparing sodium-hydrogen exchanger type 1 inhibitor |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
BR0110302A (pt) | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
HUP0300651A2 (hu) * | 2000-04-28 | 2003-07-28 | Pfizer Products Inc. | Nátrium-hidrogén-cserélő 1-es típusú inhibitor (NHE-1) alkalmazása gyógyszerkészítmények előállítására és ezt tartalmazó gyógyszerkészítmények |
US6852733B2 (en) | 2000-04-28 | 2005-02-08 | Pfizer Inc. | Sodium-hydrogen exchanger type 1 inhibitor |
IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
JP2004514706A (ja) | 2000-11-28 | 2004-05-20 | ファイザー・プロダクツ・インク | ナトリウム−水素交換体1型阻害剤の調製 |
US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
IL147696A0 (en) * | 2001-01-25 | 2002-08-14 | Pfizer Prod Inc | Combination therapy |
EP1355899A1 (en) * | 2001-01-31 | 2003-10-29 | Pfizer Products Inc. | Ethanolates of sodium-hydrogen exchanger type-1 inhibitor |
WO2002098429A1 (en) * | 2001-06-07 | 2002-12-12 | Pfizer Products Inc. | Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat |
WO2003002062A2 (en) * | 2001-06-29 | 2003-01-09 | Tularik Inc. | Bis-aryl thiazole derivatives |
JP2005511590A (ja) * | 2001-11-02 | 2005-04-28 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | アデノシンa1/a2アゴニストおよびナトリウム水素交換体阻害剤を含む医薬組成物 |
BR0215002A (pt) | 2001-12-19 | 2004-11-09 | Pfizer Prod Inc | Métodos de preparação de inibidores de permutadores de sódio-hidrogênio de tipo 1 |
EP1472242A1 (en) * | 2002-01-30 | 2004-11-03 | Pfizer Products Inc. | Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide |
WO2003092694A1 (en) * | 2002-05-02 | 2003-11-13 | Pfizer Products Inc. | Treatment of diabetes and diabetic complications with nhe-1 inhibitors |
US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
FR2840302B1 (fr) | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
FR2842525B1 (fr) * | 2002-07-16 | 2005-05-13 | Aventis Pharma Sa | Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant |
FR2842524B1 (fr) * | 2002-07-16 | 2005-04-22 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments |
FR2842526B1 (fr) | 2002-07-16 | 2007-07-13 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments |
ATE440827T1 (de) * | 2002-12-04 | 2009-09-15 | Ore Pharmaceuticals Inc | Melanocortin-rezeptormodulatoren |
CN100436445C (zh) * | 2003-02-07 | 2008-11-26 | 第一制药株式会社 | 吡唑衍生物 |
WO2005047297A1 (en) | 2003-11-12 | 2005-05-26 | Phenomix Corporation | Heterocyclic boronic acid compounds |
US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
WO2005079803A1 (en) * | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Compounds for treatment of cardiovascular diseases |
US7786163B2 (en) | 2004-07-12 | 2010-08-31 | Forest Laboratories Holdings Limited (BM) | Constrained cyano compounds |
WO2006055463A2 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
US7226942B2 (en) | 2004-11-15 | 2007-06-05 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
US7214704B2 (en) | 2004-11-15 | 2007-05-08 | Bristol-Myers Squibb Company | 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
WO2006055435A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
PL1853296T3 (pl) * | 2005-01-10 | 2012-12-31 | Debiopharm Sa | Zastosowanie cyklicznego undekapeptydu do wytwarzania leku do podawania w trakcie zdarzeń niedokrwienia mięśnia sercowego |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
WO2008005910A2 (en) | 2006-07-06 | 2008-01-10 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US8546394B2 (en) | 2007-04-17 | 2013-10-01 | Bristol-Myers Squibb Company | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors |
JP2010534722A (ja) | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
JP6022769B2 (ja) * | 2008-04-28 | 2016-11-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | プロリルヒドロキシラーゼ阻害物質としてのベンゾイミダゾール |
US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
WO2010058858A1 (ja) * | 2008-11-21 | 2010-05-27 | ラクオリア創薬株式会社 | 5-ht2b受容体拮抗活性を有する新規ピラゾール-3-カルボキサミド誘導体 |
WO2010094090A2 (en) * | 2009-02-18 | 2010-08-26 | Katholleke Universiteit Leuven | Synucleinopathies |
WO2011130459A1 (en) | 2010-04-14 | 2011-10-20 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
CN102408385B (zh) * | 2011-06-20 | 2014-06-18 | 雅本化学股份有限公司 | 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法 |
CN102408386B (zh) * | 2011-07-27 | 2014-05-07 | 雅本化学股份有限公司 | 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法 |
EP2757886A1 (de) | 2011-09-23 | 2014-07-30 | Bayer Intellectual Property GmbH | Verwendung 4-substituierter 1-phenyl-pyrazol-3-carbonsäurederivate als wirkstoffe gegen abiotischen pflanzenstress |
EP3461820B1 (en) | 2011-10-25 | 2020-07-29 | Janssen Pharmaceutica NV | Method for obtaining crystals of meglumine salt of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid |
EP2819675A4 (en) * | 2012-02-27 | 2015-07-22 | Essentialis Inc | SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF |
CN107922379B (zh) * | 2015-08-06 | 2020-11-06 | 宇部兴产株式会社 | 取代胍衍生物 |
JPWO2017057695A1 (ja) * | 2015-09-30 | 2018-07-19 | 東レ株式会社 | ジフェニルピラゾール誘導体及びその医薬用途 |
DK3395801T3 (da) * | 2015-12-16 | 2021-05-10 | Nippon Soda Co | Arylazolforbindelse og skadedyrsbekæmpelsesmiddel |
WO2018058109A1 (en) | 2016-09-26 | 2018-03-29 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2104931B1 (zh) * | 1970-09-08 | 1975-01-10 | Ferlux | |
CA2121391A1 (en) * | 1993-04-28 | 1994-10-29 | Atsuyuki Kojima | Indoloylguanidine derivatives |
IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
EP0639573A1 (de) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
DE4412334A1 (de) | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
CA2160600A1 (en) * | 1994-10-18 | 1996-04-19 | Masahumi Kitano | Indoloylguanidine derivatives |
NZ314105A (en) | 1996-02-02 | 1997-12-19 | Sumitomo Pharma | Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring |
JPH09291076A (ja) * | 1996-04-24 | 1997-11-11 | Sumitomo Pharmaceut Co Ltd | 置換グアニジン誘導体およびその製法 |
ZA9711102B (en) * | 1996-12-16 | 1998-08-13 | Yamanouchi Pharma Co Ltd | N-[(substituted 5-membered heteroaryl)carbonyl] guanidine derivative |
TR200002480T2 (tr) * | 1998-02-27 | 2000-12-21 | Pfizer Products Inc. | İzaşemi tedavisi için guanidin türevleri |
-
1999
- 1999-02-05 TR TR2000/02480T patent/TR200002480T2/xx unknown
- 1999-02-05 AU AU20706/99A patent/AU739403B2/en not_active Ceased
- 1999-02-05 AT AT99901083T patent/ATE286034T1/de not_active IP Right Cessation
- 1999-02-05 DE DE69922930T patent/DE69922930T2/de not_active Expired - Fee Related
- 1999-02-05 EA EA200000789A patent/EA003603B1/ru not_active IP Right Cessation
- 1999-02-05 EP EP04008203A patent/EP1454902A1/en not_active Withdrawn
- 1999-02-05 CA CA002321642A patent/CA2321642A1/en not_active Abandoned
- 1999-02-05 WO PCT/IB1999/000206 patent/WO1999043663A1/en not_active Application Discontinuation
- 1999-02-05 HU HU0204418A patent/HUP0204418A3/hu not_active Application Discontinuation
- 1999-02-05 NZ NZ504769A patent/NZ504769A/en unknown
- 1999-02-05 EP EP99901083A patent/EP1056729B1/en not_active Expired - Lifetime
- 1999-02-05 YU YU46200A patent/YU46200A/sh unknown
- 1999-02-05 DK DK99901083T patent/DK1056729T3/da active
- 1999-02-05 ES ES99901083T patent/ES2237080T3/es not_active Expired - Lifetime
- 1999-02-05 PT PT99901083T patent/PT1056729E/pt unknown
- 1999-02-05 ID IDW20001633A patent/ID25505A/id unknown
- 1999-02-05 JP JP2000533420A patent/JP2002504546A/ja active Pending
- 1999-02-05 KR KR10-2003-7012300A patent/KR20030083004A/ko not_active Application Discontinuation
- 1999-02-05 KR KR10-2000-7009529A patent/KR100449600B1/ko not_active IP Right Cessation
- 1999-02-05 BR BR9908332-9A patent/BR9908332A/pt not_active IP Right Cessation
- 1999-02-05 PL PL99342444A patent/PL342444A1/xx not_active Application Discontinuation
- 1999-02-05 KR KR10-2002-7017553A patent/KR100407903B1/ko not_active IP Right Cessation
- 1999-02-05 SK SK1234-2000A patent/SK12342000A3/sk unknown
- 1999-02-05 SI SI9930743T patent/SI1056729T1/xx unknown
- 1999-02-05 IL IL13658899A patent/IL136588A0/xx unknown
- 1999-02-05 US US09/367,731 patent/US6492401B1/en not_active Expired - Fee Related
- 1999-02-05 CN CN99802628A patent/CN1289326A/zh active Pending
- 1999-02-05 KR KR10-2003-7009644A patent/KR20030078886A/ko not_active Application Discontinuation
- 1999-02-22 GT GT199900022A patent/GT199900022A/es unknown
- 1999-02-22 TW TW088102574A patent/TWI226329B/zh active
- 1999-02-23 PE PE1999000156A patent/PE20000334A1/es not_active Application Discontinuation
- 1999-02-24 TN TNTNSN99028A patent/TNSN99028A1/fr unknown
- 1999-02-24 DZ DZ990032A patent/DZ2729A1/xx active
- 1999-02-24 PA PA19998468401A patent/PA8468401A1/es unknown
- 1999-02-25 AP APAP/P/1999/001478A patent/AP9901478A0/en unknown
- 1999-02-25 AR ARP990100791A patent/AR015526A1/es unknown
- 1999-02-26 ZA ZA9901578A patent/ZA991578B/xx unknown
- 1999-03-01 CO CO99012526A patent/CO4980897A1/es unknown
-
2000
- 2000-06-27 IS IS5548A patent/IS5548A/is unknown
- 2000-08-18 OA OA1200000223A patent/OA11450A/en unknown
- 2000-08-22 NO NO20004192A patent/NO20004192D0/no not_active Application Discontinuation
- 2000-08-24 HR HR20000550A patent/HRP20000550A2/hr not_active Application Discontinuation
- 2000-09-27 BG BG104803A patent/BG104803A/bg unknown
-
2001
- 2001-08-29 HR HR20010666A patent/HRP20010666A2/hr not_active Application Discontinuation
-
2002
- 2002-12-09 US US10/315,369 patent/US6974813B2/en not_active Expired - Fee Related
-
2004
- 2004-08-27 JP JP2004248129A patent/JP2005041879A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DZ2729A1 (fr) | Composés nouveaux inhibiteurs de nhe-1 procédé pour leur préparation et compositions pharmaceutiquesles contenant. | |
DZ3052A1 (fr) | Composés nouveaux inhibiteurs de métalloprotéases,procédé pour leur préparation et compositions pha rmaceutiques les contenant. | |
CY2537B1 (fr) | Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
DZ2753A1 (fr) | Hydroxamides d'acides (4-arylsulfonylamino)-tétrahydropyranne-4-carboxyliques) procédé pour leur préparation et compositions les contenant. | |
DZ2128A1 (fr) | Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2962A1 (fr) | Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant. | |
DZ2465A1 (fr) | Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions les contenant. | |
DZ2360A1 (fr) | Dérivés de pyrazole procédé pour leur préparation et compositions les contenant | |
DZ2891A1 (fr) | Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ3016A1 (fr) | Composés nouveaux inhibiteurs de réabsorption de monoamines, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2889A1 (fr) | 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant. | |
DZ2440A1 (fr) | Atropisomères de 3-aryl-4(3h)-quinazolinones procédé pour leur préparation et compositions les contenant. | |
DZ2758A1 (fr) | Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2963A1 (fr) | Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ3038A1 (fr) | Modulateurs nouveaux des récepteurs de glucocorticoïdes, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ1889A1 (fr) | Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2773A1 (fr) | Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
MA26659A1 (fr) | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. | |
DZ2745A1 (fr) | BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2890A1 (fr) | 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2777A1 (fr) | Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2358A1 (fr) | Amides inhibiteurs de sécrétion de apo b/mtp procédé pour leur préparation et compositions pharmaceutiques les contenant | |
DZ2866A1 (fr) | 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
DZ2394A1 (fr) | Dérivés de quinoléine et dérivés de quinazoline nouveax procédé pour leur préparation et compositions pharmaceutiques les contenant | |
MA26611A1 (fr) | Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant |